Cassava Sciences Reports Topline Phase 3 REFOCUS-ALZ Data
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/10/2026
- Nasdaq ends sharply higher; chip surge offsets Iran worries
- Software stocks slide as Starbucks builds AI tools to replace vendor software
- Applied Materials surges as CEO signals multi-year chip boom
- Oil prices settle 2% lower as economic worries outweigh supply risks
- Meta falls as massive AI infrastructure spending plans overshadow chip progress
- Key things to know ahead of SK Hynix’s blockbuster US listing
- Meta falls as massive AI infrastructure spending plans overshadow chip progress
- S&P Downgrades Oracle To 'bbb-/A-3'; Outlook Stable
- Software stocks slide as Starbucks builds AI tools to replace vendor software
- Citi names top picks in software ahead of Q2 earnings
Rodman & Renshaw Reiterates Sell Rating on Cassava Sciences (SAVA), PT $2
March 25, 2025 10:05 AM EDTRodman & Renshaw analyst Elemer Piros reiterated a Sell rating and $2.00 price target on Cassava Sciences (NASDAQ: SAVA).
The analyst comments "Cassava Sciences, Inc. (SAVA; Sell) announced topline results from the Phase 3 REFOCUS-ALZ study of simufilam in mild-to-moderate AD. Simufilam is a proprietary,... More
Cassava Sciences (SAVA) to Resume Trading at 8:35 a.m.
March 25, 2025 8:10 AM EDTCassava Sciences (NASDAQ: SAVA) to Resume Trading at 8:35 a.m.
